Standard BioTools Inc (NASDAQ:LAB) price on current trading day, rose 1.72% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.18.
A look at the stock’s price movement, the close in the last trading session was $1.16, moving within a range at $1.15 and $1.21. The beta value (5-Year monthly) was 1.616. Turning to its 52-week performance, $3.04 and $0.99 were the 52-week high and 52-week low respectively. Overall, LAB moved -15.71% over the past month.
Standard BioTools Inc’s market cap currently stands at around $447.20 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LAB is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend LAB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LAB’s current price about 1.72% and -17.38% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.54, while 7-day volatility ratio is 5.63% and 8.43% in the 30-day chart. Further, Standard BioTools Inc (LAB) has a beta value of 1.50, and an average true range (ATR) of 0.10. Analysts have given the company’s stock an average 52-week price target of $3.25, forecast between a low of $3.25 and high of $3.25. Looking at the price targets, the low is -175.42% off current price level while to achieve the yearly target high, price needs to move -175.42%. Nonetheless, investors will most likely welcome a -175.42% jump to $3.25 which is the analysts’ median price.
If we refocus on Standard BioTools Inc (NASDAQ:LAB), historical trading data shows that trading volumes averaged 1.67 over the past 10 days and 1.97 million over the past 3 months. The company’s latest data on shares outstanding shows there are 377.53 million shares.
The 3.18% of Standard BioTools Inc’s shares are in the hands of company insiders while institutional holders own 73.62% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.17 million on 2025-02-28, giving us a short ratio of 6.28. The data shows that as of 2025-02-28 short interest in Standard BioTools Inc (LAB) stood at 780.99996 of shares outstanding, with shares short rising to 12.85 million registered in 2025-01-31. Current price change has pushed the stock -32.57% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LAB stock continues to rise going into the next quarter.
